In patients with hyperlipidemia and cardiovascular disease, does the addition of a PCSK9 inhibitor decrease the incidence of subsequent cardiovascular events? Monroe, Lizzie; Evans, Tanner; Thacker, Thomas; More Monroe, Lizzie; Evans, Tanner; Thacker, Thomas; Streicher Green, Vanessa Less Evidence-Based Practice. 24(10):35-36, October 2021. Favorite PDF Permissions Buy
